Statin use, bone mineral density, and fracture risk - Geelong osteoporosis study

Pasco, Julie A., Kotowicz, Mark A., Henry, Margaret J., Sanders, Kerrie M. and Nicholson, Geoffrey C. (2002) Statin use, bone mineral density, and fracture risk - Geelong osteoporosis study. JAMA Internal Medicine, 162 5: 537-540. doi:10.1001/archinte.162.5.537

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ241252_fulltext.pdf Full text (open access) application/pdf 77.08KB 0

Author Pasco, Julie A.
Kotowicz, Mark A.
Henry, Margaret J.
Sanders, Kerrie M.
Nicholson, Geoffrey C.
Title Statin use, bone mineral density, and fracture risk - Geelong osteoporosis study
Journal name JAMA Internal Medicine   Check publisher's open access policy
ISSN 2168-6106
Publication date 2002-03
Sub-type Article (original research)
DOI 10.1001/archinte.162.5.537
Open Access Status File (Publisher version)
Volume 162
Issue 5
Start page 537
End page 540
Total pages 4
Place of publication Chicago, IL, United States
Publisher American Medical Association
Language eng
Formatted abstract
Background: Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease fracture risk and increase bone mineral density (BMD).

Methods: This cross-sectional study is set in southeastern Australia. We evaluated the association between statin use, fracture risk, and BMD in 1375 women (573 with incident fractures and 802 without incident fracture, all drawn from the same community). Fractures were identified radiologically. Medication use and lifestyle factors were documented by questionnaire.

Results: Unadjusted odds ratio for fracture associated with statin use was 0.40 (95% confidence interval [CI], 0.23-0.71). Adjusting for BMD at the femoral neck, spine, and whole body increased the odds ratio to 0.45 (95% CI, 0.25-0.80), 0.42 (95% CI, 0.24-0.75), and 0.43 (95% CI, 0.24-0.78), respectively. Adjusting for age, weight, concurrent medications, and lifestyle factors had no substantial effect on the odds ratio for fracture. Statin use was associated with a 3% greater adjusted BMD at the femoral neck (P=.08), and BMD tended to be greater at the spine and whole body but did not achieve statistical significance.

Conclusion: The substantial 60% reduction in fracture risk associated with statin use is greater than would be expected from increases in BMD alone.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 122 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 24 May 2011, 14:54:19 EST by System User on behalf of Rural Clinical School